Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
ARISTOCORT is an injectable small-molecule corticosteroid approved in 1961 for anti-inflammatory and immunosuppressive indications. The exact therapeutic indications are not specified in available data, but the injectable route suggests use in localized or systemic inflammatory conditions. As a legacy product, it represents a mature therapeutic class with established clinical utility.
Product approaching loss of exclusivity with low linked job openings, indicating a mature brand with minimal commercial expansion and likely stable but small team size.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ARISTOCORT offers limited career growth opportunities due to its mature, LOE-approaching status and zero linked job postings. This role suits professionals seeking stability in legacy product management or those building expertise in corticosteroid compliance and niche market stewardship rather than growth-stage innovation.
Worked on ARISTOCORT at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.